The findings on tumor mutational burden (TMB) may fill a gap in biomarkers for patients who have non–small cell lung cancer (NSCLC). The findings could make it easier for clinicians to personalize ...
In contrast to what has been seen in other types of cancer, in which high tumor mutational burden (TMB) predicts response to immunotherapy, the situation appears to be reversed in cases of recurrent ...
A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results